|
|
|
Volumn 12, Issue 2, 2001, Pages 122-123
|
|
Carvedilol saves lives - New data from landmark trials prove survival benefits in heart failure and post myocardial infarction
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA 1 ADRENERGIC RECEPTOR;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CARDIOL;
CARVEDILOL;
COROPRES;
ANTIOXIDANT ACTIVITY;
CARDIOVASCULAR DISEASE;
CELL PROLIFERATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
DRUG TOLERABILITY;
HEART FAILURE;
HEART INFARCTION;
HEART LEFT VENTRICLE FAILURE;
HEMODYNAMIC MONITORING;
HUMAN;
HYPERTENSION;
ISCHEMIC HEART DISEASE;
LONG TERM CARE;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
RECURRENCE RISK;
RISK ASSESSMENT;
SURVIVAL;
VASODILATATION;
ADRENERGIC BETA-ANTAGONISTS;
CARBAZOLES;
CLINICAL TRIALS;
HEART FAILURE, CONGESTIVE;
HUMANS;
MYOCARDIAL INFARCTION;
PROPANOLAMINES;
SURVIVAL RATE;
VENTRICULAR DYSFUNCTION, LEFT;
|
|
EID: 0034849564
PISSN: 10159657
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|